How to Leverage Medical Device Registration Dossiers Across GHWP Member States

Summary

The GHWP (Global Harmonization Working Party) includes dozens of countries and regions such as China, Japan, South Korea, Singapore, Brazil, and Russia. While registration dossiers share some commonalities, reusing them is not merely a matter of translation. Companies should first determine whether the product falls under the medical device regulatory scope of the target country, then select the registration pathway based on risk classification (e.g., China NMPA, Japan PMDA, South Korea MFDS). Reusable core technical documents include ISO 13485 quality system certificates, MDSAP audit reports, risk management reports (ISO 14971), certain performance validation reports (e.g., electrical safety, biocompatibility), and clinical evaluation reports (if based on the same standards). However, the following documents must be localized: labels and instructions for use (language and local format), registration application forms, local agent or authorized representative information, post-market surveillance plans, and certain clinical evidence (e.g., local clinical data requirements). Common risks include: invalid dossiers due to unverified product classification differences, neglecting local regulatory changes, unclear agent responsibilities, and loss of control over certificates. Companies should establish a multi-country registration dossier matrix early in the project, clearly identifying reusable and localizable items, and sign responsibility agreements with local agents to reduce the cost of repeated corrections.

Applicable Scenarios and Core Issues

Reusing GHWP member state medical device registration dossiers is applicable when a company plans to submit registration applications in multiple GHWP member states simultaneously or sequentially. The core question is: which documents can be directly translated and used? Which must be regenerated or adjusted? The main barrier is the company's varying understanding of each country's regulatory framework. For example, China's NMPA requires a fixed format for product technical requirements, while Brazil's ANVISA places more emphasis on INMETRO certification. Japan's PMDA may require additional clinical performance data. Companies cannot assume that all member states will accept the same technical documents; they must verify each country's registration guidelines individually.

Common applicable products include Class II and above active devices, in vitro diagnostics, and implants, as their technical documentation is more complete and offers high reuse value. Low-risk Class I products have simple dossiers, making reuse less meaningful.

Registration Judgment Logic

• Step 1: Determine whether the product qualifies as a medical device in the target country. For example, in South Korea, certain software may be classified as digital health devices rather than medical devices, leading to a different registration pathway.
• Step 2: Determine the risk classification (e.g., EU classification, China classification, Japan classification). Different classifications correspond to different registration pathways and documentation requirements. For example, in China, Class II devices are reviewed by provincial authorities, while Class III devices are reviewed at the national level; Japan's PMDA offers simplified review for some Class II products.
• Step 3: Assess the gap between existing documentation and the target country's requirements. Check: Does the technical file include a risk management report per ISO 14971? Are biocompatibility tests per ISO 10993 available? Are electrical safety standards based on the IEC 60601 series? Has an MDSAP audit been obtained?
• Step 4: Decide on the applicant entity. A local agent or authorized representative is typically required, especially in China, Brazil, and Russia.
• Step 5: Confirm post-market maintenance requirements, such as periodic updates, adverse event reporting, and certificate renewals.

Documents and Evidence

Reusable Documents

• ISO 13485 certificate (preferably in MDSAP format)
• Risk management report (if risk analysis is globally applicable)
• Basic electrical safety and EMC test reports (if standards are consistent, e.g., IEC 60601-1)
• Biocompatibility tests (ISO 10993 series)
• Performance validation data (e.g., accuracy, repeatability)
• Software verification documentation (e.g., IEC 62304)
• Clinical evaluation report (if based on international literature, core parts can be generic)

Documents That Must Be Localized

• Product labels and instructions for use (language, units, warnings per local requirements)
• Registration application form (format and content vary)
• Local agent authorization letter (notarization or certification requirements differ)
• Post-market surveillance plan (reporting deadlines vary by country)
• Supplemental clinical evidence (e.g., Japan may require clinical data on Asian populations)
• Free sale certificate (some countries require local issuance)

Common Pitfalls

The most frequent mistake companies make is treating the registration project as a simple document submission, without first clarifying product classification, evidence coverage, and local responsibility relationships.

• Translating domestic NMPA dossiers directly without reorganizing evidence according to the target market pathway.
• Having too many model/version numbers without sufficient testing reports, clinical evidence, or label coverage.
• Selecting a local agent solely based on sales cooperation, without clarifying regulatory responsibilities, certificate control, and post-market maintenance duties.
• Inconsistencies among labels, instructions, promotional materials, and registration dossiers, leading to correction requests or post-market compliance risks.
• Failing to plan for multi-country dossier reuse in advance, resulting in redundant work per country, increasing both cost and timeline.

Company Preparation Checklist

1. Establish a multi-country registration dossier matrix: list required documents for each country, mark reusable and localizable items.
2. Confirm quality system certification: obtain MDSAP if possible to reduce repeated audits.
3. Prepare core technical documents in English: ensure risk management, performance validation, and clinical evaluation files are in the latest format.
4. Obtain a free sale certificate: from the country of origin or the first approved country; some countries require notarization.
5. Select and contract a local agent: define scope, fees, and intellectual property ownership.
6. Perform language localization: engage professional translation and review for terminology accuracy.
7. Develop a post-market maintenance plan: assign staff to monitor changes and renewal deadlines per country.
8. Budget for supplemental testing: e.g., local clinical data requirements or sample testing.

AIMEILI Regulatory Interpretation

The most common misjudgment by companies is assuming that “GHWP member states have unified guidelines, so dossiers can be copied directly.” In reality, GHWP only provides a harmonization framework; specific implementation still varies by country. Early in the project, a gap analysis should be conducted, focusing on product classification, standard versions, and clinical evidence requirements. Core technical documents (risk management, performance testing, partial clinical evaluation) have high reuse value, but labels, instructions, agent documents, and post-market plans must be localized. For multi-country registration, it is recommended to centralize certificate control (e.g., designate the parent company as the certificate holder) to avoid losing control due to agent changes. Changes and renewals must be tracked promptly, as each country has different timelines. Companies should assign dedicated regulatory personnel to liaise with local agents or engage experienced consulting firms to reduce the risk of correction requests.

Frequently Asked Questions

Q1: If a product is already registered in China, can the dossier be used directly for Japan registration?

No. While the Chinese registration dossier can serve as a reference, it must be supplemented with Japan-specific requirements, such as PMDA-format application forms, Japanese-language instructions, test reports from Japan GLP-certified laboratories (if required), and clinical data on Asian populations (depending on product risk). Additionally, Japan requires a local agent's authorization letter and accepts ISO 13485 certificates but may impose additional on-site audits.

Q2: Can MDSAP fully replace each country’s quality system audit?

Not entirely. MDSAP (Medical Device Single Audit Program), promoted by GHWP, covers quality system audits for the US, Japan, Brazil, Australia, and Canada. For other GHWP member states (e.g., South Korea, China), MDSAP is not yet officially recognized as a substitute for local system audits, but it can serve as supporting evidence to reduce audit frequency. Companies still need to maintain quality system documents compliant with local requirements.

Q3: When registering in multiple countries, should technical files be bound separately for each country?

It is not recommended to split the file. Instead, prepare a complete English technical file (including all test reports, risk analysis, and clinical evaluation), then extract relevant sections for each target country and add country-specific application forms and instructions. This maintains data consistency and avoids version confusion that could lead to reviewer queries.

Practical Implementation Recommendations

In actual projects, companies should break this issue into five tasks: regulatory determination, dossier preparation, evidence reuse, localization conversion, and post-market maintenance. This ensures that gaps are identified early and that sales, R&D, quality, and regulatory teams develop a consistent understanding of each target country's requirements. If a company plans to enter multiple markets simultaneously, it is advisable to first create a unified core technical file, then supplement with authorization, labels, language, forms, and local agent documentation for each country. The efficiency of multi-country registration often depends on the uniformity of the upfront dossier framework, rather than the speed of submission in individual countries.